Angiotensin receptor blockers (ARBs) were developed to better antagonize the effects of
chronic overactivation of angiotensin II. In clinical studies, ARBs have consistently been …

The cardiovascular continuum describes the progression of pathophysiologic events from
cardiovascular risk factors to symptomatic cardiovascular disease (CVD) and life-threatening …

In the prevention and treatment of cardiovascular disease, pharmacological treatment
strategies should have several aims:(i) in individuals without overt cardiovascular disease …

The ability of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor
blockers (ARBs) to lower blood pressure (BP) is well established. ACE inhibitors (ACE-Is) …

With the fanfare associated with the introduction of angiotensin II receptor blockers (ARBs) 6
years ago, there was an immediate assumption that they would replace the angiotensin …

Cardiovascular and renal disease can be regarded as progressing along a sort of
continuum which starts with cardiovascular risk factors (hypertension, diabetes …

In this article, 2 leading physicians debate the strength of outcome data on the efficacy of
angiotensin-converting enzyme (ACE) inhibitors versus angiotensin II receptor blockers …

Angiotensin II type 1 receptor blockers (ARBs) are generally as effective as angiotensin-
converting enzyme (ACE) inhibitors in patients with hypertension. However, inhibition of …

Objectives: We sought to determine the effect of angiotensin receptor blockers (ARBs) on
mortality and hospitalization in patients with heart failure (HF). Background: There is …

Although interruption of the renin-angiotensin system with angiotensin converting enzyme
(ACE) inhibitors has evolved as the therapy of choice in heart failure based on large-scale …